{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:43:58Z","timestamp":1764510238402},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,6,19]],"date-time":"2002-06-19T00:00:00Z","timestamp":1024444800000},"content-version":"vor","delay-in-days":79,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2002,4]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold>  <jats:italic>Objectives<\/jats:italic>\n          : To evaluate therapeutic results and prognostic factors from a series of 44 patients affected by \n          <jats:italic>de novo<\/jats:italic>\n           acute myeloid leukemia with multilineage dysplasia (MD\u2010AML), treated with the combination of fludarabine, cytarabine and G\u2010CSF (FLAG). \n          <jats:italic>Methods<\/jats:italic>\n          : Forty\u2010four patients with \n          <jats:italic>de novo<\/jats:italic>\n           MD\u2010AML were treated with the FLAG regimen. The median age was 61\u2003yr (range 31\u201375\u2003yr). Induction therapy consisted of the FLAG regimen; consolidation included idarubicin plus cytarabine. Patients with a compatible donor and aged less than 55\u2003yr were programmed to receive allogeneic bone marrow transplantation (BMT), while in those without a donor and aged less than 65\u2003yr autologous transplantation with peripheral blood stem cells mobilized by a consolidation regimen plus G\u2010CSF was planned. Bone marrow harvest was performed in poor mobilizers. \n          <jats:italic>Results<\/jats:italic>\n          : Complete remission (CR) was achieved in 28 out of 44 patients (64%). Death in induction occurred in four patients (9%), while 12 patients (27%) were resistant to FLAG. Toxicity of consolidation was negligible. Most patients aged less than 60\u2003yr and achieving CR were eligible for transplantation procedures, the main reason of exclusion being early relapse. Median overall survival and disease free survival were 16 and 22 months, respectively. Unfavorable cytogenetics was the only parameter significantly related to inferior clinical outcome following multivariate analysis. \n          <jats:italic>Conclusion<\/jats:italic>\n          : Multilineage dysplasia \n          <jats:italic>per se<\/jats:italic> is not an adverse prognostic factor in AML patients treated with the FLAG regimen. Favorable results are obtained in patients with intermediate karyotype, while in those with adverse cytogenetics new approaches are clearly needed. The toxicity of the regimen is also acceptable in the elderly, and following induction\/consolidation, most patients may be submitted to transplantation procedures.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2002.01651.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:52:56Z","timestamp":1047408776000},"page":"203-209","source":"Crossref","is-referenced-by-count":32,"title":["<i>De novo<\/i> acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G\u2010CSF (FLAG)"],"prefix":"10.1111","volume":"68","author":[{"given":"Felicetto","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pocali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filiberto","family":"Pollio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assunta","family":"Viola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Sebastio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore Mariano","family":"Schiavone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Mele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Gianfaldoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,6,19]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1987.tb01325.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_5_4_2","first-page":"520","article-title":"Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival","volume":"6","author":"Goasguen JE","year":"1992","journal-title":"Leukemia"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1990.tb01111.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04827.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050320"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401924"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.671"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90066.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-8652(199806)58:2<105::aid-ajh3>3.3.co;2-3"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050533"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2006::AID-CNCR18>3.0.CO;2-2"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02551.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.116"},{"key":"e_1_2_5_16_2","first-page":"826","article-title":"Kinetic rationale for cytokine\u2010induced recruitment of myeloblastic leukemia followed by cycle\u2010specific chemotherapy in vitro","volume":"4","author":"Tafuri A","year":"1990","journal-title":"Leukemia"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01737421"},{"key":"e_1_2_5_18_2","first-page":"1480","article-title":"Hematopoietic growth factor stimulation and cytarabine toxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells","volume":"8","author":"Te Boekhorst PA","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-4-620"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1295"},{"key":"e_1_2_5_21_2","first-page":"95","article-title":"Morphology and classification of the myelodysplastic syndromes and their pathologic variants","volume":"33","author":"Kouides PA","year":"1996","journal-title":"Semin Hematol"},{"key":"e_1_2_5_22_2","volume-title":"Supplement to: an International System for Human Cytogenetic Nomenclature.","author":"ISCN Guidelines for Cancer Cytogenetics","year":"1995"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML. Analysis of 1612 patients entered into the MRC AML 10 Trial","volume":"92","author":"Grimwade D","year":"1998","journal-title":"Blood"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1312"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_5_26_2","first-page":"38","volume-title":"WHO Handbook for Reporting Results of Cancer Treatment.","author":"World Health Organization.","year":"1979"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200122"},{"key":"e_1_2_5_28_2","first-page":"143","article-title":"Effect of fludarabine and arabinosilcytosine on multidrug\u2010resistant cells","volume":"82","author":"Michelutti A","year":"1997","journal-title":"Haematologica"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199809068573"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(00)00122-0"},{"key":"e_1_2_5_31_2","first-page":"124","article-title":"Hematopoietic growth factors in acute myeloid leukemia. Supportive and priming effects","volume":"24","author":"Buchner T","year":"1997","journal-title":"Semin Oncol"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400561"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01379.x"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4763281.x"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2819"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0142(19990401)85:7<1506::aid-cncr11>3.0.co;2-o"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402113"},{"key":"e_1_2_5_38_2","first-page":"531","article-title":"Current uses of monoclonal antibodies in the treatment of acute leukemia","volume":"27","author":"Ruffner KL","year":"2000","journal-title":"Semin Oncol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2002.01651.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2002.01651.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2002.01651.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T08:08:15Z","timestamp":1697530095000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2002.01651.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["10.1034\/j.1600-0609.2002.01651.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2002.01651.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}